ARCHIVES

Adjuvant XELOX More Effective Than 5-FU/LV For Stage III Colon Cancer

This article is from The Cancer Letter archive.

Vol. 33 No. 1 | January 29, 2010

Download PDF Visit The Full Archive

Related Articles

Matrisian, Nelson, to lead review of NCI translational research programs.

September 23, 2005

Academic Oncologists Losing Control Over Phase I Trials As For-Profits Expand

March 26, 2010

NIH Consensus Panel Urges Wider Use of Pap Test

April 12, 1996

Trombold Tells How Scripps Raises Money for Cancer Center, Gets Independent From “Whiny Administrator”

April 5, 1985

NCI CTEP-Approved Trials For the Month of February

February 28, 2014

FDA Policy On Support Of Medical Education Near Final Form

February 5, 1993